About US
Contact us
-
FDA approves Darzalex combination for multiple myeloma treatmentThe US Food and Drug Administration (FDA) has approved the combined use of Darzalex (daratumumab) with bortezomib, thalidomide and dexamethasone (Vtd) as a frontline treatment for patients who are el2019/9/17
-
Avanir resolves Nuedexta kickback lawsuits for $116mCalifornia-based Avanir has resolved and settled multiple civil, criminal and administrative lawsuits in the US alleging corrupt sales and marketing practices of its drug Nuedexta (dextromethorphan H2019/9/17
-
Teva subsidiary inks distribution deal with Israeli medical marijuana product makerAs drugmakers dip their toes into the water of cannabis-based drugs, major companies have so far mostly shied away from diving in. Now, a Tevasubsidiary is looking for the on-ramp with a distribution2019/9/16
-
ECTRIMS: Novartis' Mayzent delays wheelchair use by 4-plus years for MS patientsNovartis is working to change doctors’ “psychology” around the treatment of secondary progressive multiple sclerosis (SPMS). And new disability data for its drug, Mayzent, should help its case. On av2019/9/16
-
Roche's Tecentriq scores solo win in lung cancer. But can it challenge Merck's Keytruda?Roche, late to the scene in non-small cell lung cancer, has been looking to capture share from Merck with its Tecentriq-chemo combo. And it just got one step closer to bringing its quest to the monot2019/9/12
-
Who joins Purdue on pharma's top 10 settlements list? Merck, GSK and Pfizer, for startersPurdue’s pending opioid settlement with thousands of cities and counties, worth between $10 billion and $12 billion, could rank as the largest deal ever inked by a pharma if it passes a Cleveland fed2019/9/12
-
Vertex strikes deal for Orkambi and Symkevi in Scotland, ramping up pressure on holdout EnglandVertex Pharmaceuticals and English health officials have for years been unable to strike a deal for cystic fibrosis drug access, but Vertex's new deal with neighbor Scotland may pile on the pressure.2019/9/11
-
Purdue inks multibillion-dollar opioid deal with thousands of local governments, more than 20 states: reportsPurdue Pharma has entered the first major opioid settlement. The company, whose OxyContin played a role in the opioid epidemic, plans to file for bankruptcy imminently and restructure under an agreem2019/9/11
-
Xeris scores first FDA nod with shelf-stable glucagon injector, syringeDiabetes drugmaker Xeris Pharmaceuticals made a $75 million bet last summer when it went public to back an FDA submission for its shelf-stable glucagon injector pen. Now, more than a year later, Xeri2019/9/10
-
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera dataThe multiple sclerosis field has grown increasingly competitive in recent years, but now Biogen is touting data the drugmaker believes will give its established Tecfidera an edge new rivals can’t mat2019/9/10